Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Laura on +441494 818 026 or laura@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Laura Marsh
Account Manager
laura@zenopa.com
+441494 818 026

Testimonials
I was really impressed with the recruitment experience which Zenopa provided. Initially meeting with them face to face was important as we could gage which roles would be right for me.
Daniel , 2013

Merck Sharpe and Dohme expands partnership with NicOx

21 September 2010 00:00 in Pharmaceutical Company Product News


Merck Sharpe and Dohme is to expand the scope of its global licence agreement with French pharmaceutical company NicOx in order to develop a new type of treatment.

The two companies' ongoing research programme, which commenced in 2006, has yielded a new approach to nitric oxide (NO) donation, which could be used to create new classes of NO-donating molecular entities with therapeutic potential.

Merck has therefore moved to secure the rights to develop these entities against a number of cardiovascular targets, while NicOx will produce candidate drugs for other indications.

The new agreement will see both firms pay their partner milestone sums based on the future developmental and commercial success of any products created via this new method.

Ennio Ongini, vice-president for research at NicOx, said: "The research collaboration with Merck has been very fruitful and it is as a result of the excellent scientific interaction that this new approach to NO donation was discovered."

Last week, Merck Sharpe and Dohme was granted European regulatory approval for a new indication of its drug Ivemend, which helps to provide relief against chemotherapy-induced nausea and vomiting.ADNFCR-8000103-ID-800073809-ADNFCR

Other news stories from 21/09/2010

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd